Get the Daily Brief
Latest Biotech News
Kite and Pregene tie up for in vivo CAR‑T development — big payments on table
Gilead’s Kite Pharma struck a multi-partner collaboration with Chinese biotech Pregene Biopharma to accelerate in vivo CAR‑T and related next‑generation cell therapies, with the agreement carrying...
Novo Nordisk buys Omeros’ MASP‑3 candidate — $2.1B upside
Novo Nordisk agreed to acquire global rights to zaltenibart (OMS‑906), an antibody that inhibits MASP‑3 in the complement pathway, from Omeros in a deal valued at up to $2.1 billion including...
Tubulis secures record ADC Series C — clinical expansion funded
German ADC specialist Tubulis closed an oversubscribed Series C round—one of the largest European private raises this year—to accelerate clinical development of its lead antibody‑drug conjugate...
Boehringer licenses Aimedbio’s solid‑tumor ADC — near‑$1B deal
Boehringer Ingelheim agreed to license a preclinical antibody‑drug conjugate from Aimedbio that targets proteins expressed broadly in solid tumors, in a deal valued at up to roughly $991 million....
Illumina’s Constellation mapped reads show promise in GeneDx pilot
At ASHG, GeneDx presented early results from a pilot using Illumina’s Constellation mapped‑read technology on NovaSeq X Plus instruments, demonstrating improved detection of historically difficult...
DeepSomatic: cross‑platform deep learning advances somatic variant calling
Researchers published DeepSomatic in Nature Biotechnology describing a deep‑learning pipeline for accurate somatic small‑variant discovery across short‑ and long‑read sequencing technologies. The...
CDMO capacity builds as Lonza opens potent biologics line and Merck unit buys JSR chromatography
Lonza announced Swissmedic approval for a new aseptic drug‑product filling line in Stein (CH) designed for highly potent biologics, enhancing capacity for liquid and lyophilized vials and meeting...
Plasmidsaurus launches ultrafast RNA‑Seq service — three‑day workflows
Plasmidsaurus unveiled an RNA‑Seq service tailored for Illumina short‑read applications promising rapid turnaround times—culture or crude cell preps to analyzed data in as little as three days....
Genomics Ltd debuts Mystra AI platform to de‑risk targets for drug developers
British genomics company Genomics Ltd launched Mystra, an AI‑enabled genomics platform designed to speed target and biomarker discovery by integrating data from ~20,000 GWAS and trillions of data...
Novo Nordisk Bets $2.1 Billion on Omeros’ MASP-3 Drug: Zaltenibart Deal
Novo Nordisk agreed to acquire global rights to Omeros’ MASP-3 inhibitor zaltenibart in a deal worth up to $2.1 billion, marking a rapid strategic move into complement‑mediated rare diseases. Novo...
Praxis Clears Doubts — Two Phase 3 Wins for Essential Tremor
Praxis Precision Medicines reported positive Phase 3 results for its ulixacaltamide program in essential tremor, meeting primary endpoints in two studies and reversing a prior interim concern in...
J&J Sees Survival Boost with Darzalex–Tecvayli Combo in Myeloma
Johnson & Johnson reported data showing a Darzalex (daratumumab) plus Tecvayli (teclistamab) combination improved survival metrics in multiple myeloma patients, supporting use of dual‑targeting...
Aicuris’ Oral Herpes Drug Succeeds in Phase 3 — FDA Filing Next
Aicuris reported Phase 3 success for pritelivir in immunocompromised patients with refractory HSV infections, meeting endpoints versus standard‑of‑care and setting up plans for a U.S. regulatory...
Tubulis Raises Record Series C to Push ADC Program
Tubulis closed a €308 million (≈$356 million) Series C — one of Europe’s largest biotech rounds this year — to advance its next‑generation antibody‑drug conjugates (ADCs), notably TUB‑040 in...
Long‑Read Sequencing Costs Drop — PacBio Reusable Consumables Move
Pacific Biosciences announced plans to allow reuse of its most expensive consumables and rolled out Sprq‑Nx chemistry to boost output, targeting sub‑$300 per genome costs for large projects. The...
Manufacturing Capacity Grows — Lonza Line Approved, MilliporeSigma M&A
Lonza received Swissmedic approval for a new aseptic filling line in Stein capable of handling highly potent biologics and ADCs, expanding its drug product footprint and containment capabilities....
In Vivo Immune Programming and LNP Startups Gain Traction
Create Medicines (formerly Myeloid Therapeutics) announced a strategic rebrand and expanded its in‑vivo mRNA‑LNP immune programming platform beyond myeloid cells to include T and NK cell...
mRNA Manufacturing and Purification Get Regional and Technical Boosts
BioNTech secured up to €95 million from two EU bodies to support construction of an mRNA vaccine facility in Kigali, Rwanda, advancing regional vaccine production capacity in Africa. The funding...
Big Obesity Bets — Kailera $600M Series B and Lilly’s Oral GLP‑1 Wins
Kailera Therapeutics closed a $600 million Series B led by Bain Capital Private Equity to advance KAI‑9531, a weekly dual‑target metabolic injection positioned against Eli Lilly’s obesity...
Novo Nordisk lands Omeros’ MASP‑3 inhibitor: $2.1B pact
Novo Nordisk agreed a development and commercialization deal giving it global rights to zaltenibart, an Omeros MASP‑3 antibody, with up to $2.1 billion in payments tied to milestones. Novo will...